PT.CSIJ.252F.C God.7).
Approved for use through 03x02x07 CMB GS1 and U.S. Palent and Tendemark Office, U.S. DEPARTMENT OF COMMERCE.
U.S. Palent and Tendemark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Poperators Reduction Act of 1995, no persons are required to respond to a collection of information unless of contains a year old CMB control charge.

Application Number   10646242   Filling   2003-08-22   Docket Number (if applicable)   330244   Art   2416   Trist Named Inventor   Sarkar   Examiner Name   Soakye, Alexander O.    This is a Request for Continued Examination (RCE) practice under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 of the above-identified application filed prior to June 1995, or to any design application. The Instruction Sheet for this form is located at WWW.USPTO.GOV    Substitution   Substitu		REC	QUEST FO	OR CONTINU	ED EXAMINATION FOR THE PROPERTY OF THE PROPERT	N(RCE)TRANSN	NITTAL				
First Named Sarkar    Sarkar		10646242		1	Docket Number	I		2416			
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 1995, or to any design application. The Instruction Sheet for this form is located at WWW,USPTO,GOV  SUBMISSION REQUIRED UNDER 37 CFR 1.114  Note: If the RCE is proper, any previously filed unentiared amendments and amendments enclosed with the RCE will be entered in the crici in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment, entered, applicant must request non-entry of such amendments).  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		Sarkar			Examiner						
Note: If the RCE is proper, any previously filed unentiared amendments and amendments enclosed with the RCE will be entered in the circle in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment, entered, applicant must request non-entry of such amendments, or survivously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on  Other  Enclosed  Amendment/Reply  Information Disclosure Statement (IDS)  Affidevit(s)/ Declaration(s)  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	Request for C	ontinued Exami	nation (RCE)	practice under 37	CFR 1,114 does not at	oply to any utility or plan	cation, et application filed	prior to June l			
in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(sherted, applicant must request non-entry of such amendment(sherted).  Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on  Other  Enclosed  Amendment/Reply  Information Disclosure Statement (IDS)  Affidevit(s)/ Declaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hereby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			8	UBMISSION RE	QUIRED UNDER 37	CFR 1.114					
□ submission even if this box is not checked. □ Consider the arguments in the Appeal Brief or Reply Brief previously filed on □ Other □ Consider the arguments in the Appeal Brief or Reply Brief previously filed on □ Other □ Consider the arguments in the Appeal Brief or Reply Brief previously filed on □ Other □ Amendment/Reply □ Information Disclosure Statement (iDS) □ Affidavit(s)/ Declaration(s) □ Other □ MISCELLANEOUS □ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months □ (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) □ Other □ FEES □ The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. □ The Director is hareby auditorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170226 □ SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED □ Patent Practitioner Signature	in which they	were filed unless	s applicant in	structs otherwise.	If applicant does not wi	nents enclosed with the sh to have any previous	RCE will be enterly flied unentered	red in the orde I amendment(s			
□ Other  Enclosed □ Amendment/Repty ☑ Information Disclosure Statement (IDS) □ Affidavit(s)/ Declaration(s) □ Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of auspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) □ Other  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.17(i) required of the representation of the proof of the representation of the represe	Previously submission	submitted, If a n even if this bo	final Office a x is not chec	ction is outstanding ked.	g, any amendments file	d after the final Office a	ction may be cor	sidered as a			
Enclosed  Amendment/Repty  Information Disclosure Statement (IDS)  Affidav/t(s)/ Declaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a pariod of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	Consider the arguments in the Appeal Brief or Reply Brief previously filed on										
Amendment/Reply  Information Disclosure Statement (IDS)  Affidavit(s)/ Declaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	O#	er									
Information Disclosure Statement (IDS)     Affidevit(s)/ Declaration(s)     Other     MiSCELLANEOUS     Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)     Other     Other     FEES     The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.     The Director is hereby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226     SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED     Patent Practitioner Signature	X Enclosed	***************************************									
Affidevit(s)/ Deciaration(s)  Other  MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of auspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.17(i) required)  The Director is hereby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:26  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	Amendment/Reply										
Other   MISCELLANEOUS	X Information Disclosure Statement (IUS)										
MISCELLANEOUS  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:26  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	Affidavit(s)' Declaration(s)										
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months  (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)  Other  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	☐ OII	ner									
Cither  Cither  FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature				M	SCELLANEOUS		***************************************				
FEES  The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby autitorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170226  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature							od of months				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.  The Director is hareby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170:26  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature	Other			******							
The Director is hareby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No 170326  SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED  Patent Practitioner Signature					FEES						
Patent Practitioner Signature	X The Dire	ctor is hereby as	thorized to c								
Sensity of			SIGNATUR	RE OF APPLICA	NT, ATTORNEY, OR	AGENT REQUIRED	:				
Applicant Signature	*****		nature								

Signature of Registered U.S. Patent Practitioner							
Signature	C Gen	Date (YYYY-MM-DD)	2009-09-14				
Name	Charles Eggers	Registration Number	56343				

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to fife (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. 0.12 and 35 U.S. 0.12 and 37 I.This collection is estimated to take 12 minutes to complete, including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the includingual case. Any comments on the amount of time you require to complete this form and or supersions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Sox 1450, Assandria, NA 23131-4500.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) lumishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish requested information, the U.S. Patient and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cord s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement necotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.Sc. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(t) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.